Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imeglimin - Poxel

Drug Profile

Imeglimin - Poxel

Alternative Names: EMD-387008; Imeglimin hydrochloride - Poxel; PXL 008; RVT-1501; TWYMEEG

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer Poxel; Sumitomo Pharma
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines; Urologics
  • Mechanism of Action Insulin secretion stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Kidney disorders

Most Recent Events

  • 23 Mar 2023 Launched for Type 2 diabetes mellitus in India (PO), prior to March 2023
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 28 Dec 2021 No recent reports of development identified for phase-I development in Kidney-disorders(In the elderly, In adults) in Japan (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top